Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of unoprostone release drug (URD) in retinitis pigmentosa
jRCT2021190021Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unoprostone isopropyl in retinitis pigmentosa (RP), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Plasma concentration of unoprostone and M1, Blood test and 3 more. Started Mar 2020; status: active, not recruiting.
02
Drugs
unoprostone isopropyl
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2021190021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021190021.